Issue: January 10, 2016

January 10, 2016

1 min read

Save

This article is more than 5 years old. Information may no longer be current.

Lung Cancer Drugs in the Pipeline

Issue: January 10, 2016

HemOnc Today presents this guide to drugs in phase 2 or phase 3 development for lung cancer-related indications. Clinicians can use this chart as a quick reference to learn about the status of those drugs that may be clinically significant to their practice.

Lung Cancer Drugs in the Pipeline — Information in this chart was compiled from the Pharmaceutical Research and Manufacturers of America, NIH (www.clinicaltrials.gov), corporate websites and the databases of HemOnc Today. The publisher or editors do not assume responsibility for any errors or omissions.